Exercise Improves Cardiovascular Health More Than Weight-Loss Drugs After Weight Loss
A study conducted by researchers at the University of Copenhagen has revealed that individuals with severe obesity who engage in regular exercise exhibit healthier blood vessels and reduced inflammation compared to those who rely solely on medication for weight management. This research sheds light on the broader implications of weight-loss strategies beyond mere weight reduction, emphasizing the importance of physical activity for cardiovascular health.
The study followed 130 participants who had undergone a low-calorie diet, resulting in an average weight loss of 13.7 kg (30.2 lbs). After this initial phase, participants were divided into four distinct groups: those who exercised only, those who were treated with liraglutide (a weight-loss medication), those who combined exercise with liraglutide, and a placebo group. The findings indicated that participants who engaged in regular exercise not only maintained their weight loss but also experienced significant improvements in their vascular health.
Specifically, the exercise group demonstrated a 6-7% reduction in carotid artery wall thickness, a key marker for cardiovascular risk, while no such improvements were observed in the liraglutide-only or placebo groups. Additionally, levels of inflammatory markers, which are critical in the development of cardiovascular diseases, decreased among those who exercised.
Rasmus Sandsdal, a medical doctor and PhD student involved in the study, noted that while medications can assist in maintaining weight loss, exercise offers additional health benefits that medications alone cannot provide. The exercise regimen did not require intense training; participants averaged about two and a half hours of physical activity per week, primarily through spinning and circuit training, with activity levels monitored using heart-rate monitors.
The researchers highlighted the encouraging nature of these findings, particularly since the participants were relatively healthy individuals in their mid-40s who had not yet developed diabetes or heart disease. This suggests that even modest amounts of exercise can significantly enhance key risk factors for cardiovascular disease.
While the study focused on liraglutide, an earlier generation of GLP-1 weight-loss medication, the researchers caution that the results may not directly apply to newer medications like semaglutide (e.g., Wegovy). Nevertheless, they stress that exercise should remain a fundamental component of treatment for severe obesity, especially as the use of weight-loss medications becomes more prevalent.
In conclusion, the study underscores the critical role of physical activity in protecting heart and vascular health, reinforcing the notion that while weight-loss medications are valuable tools, they cannot replace the health benefits derived from regular exercise. The findings were published in the journal Nature Metabolism.




